This website uses cookies. By continuing you are agreeing to our privacy policy.

Peter Kaiser, PhD

Research Awards Nationwide Recipient (2014-2016)

University of California, Irvine
Drugs to Reactivate Tumor-Killing Ability of p53

One of the most commonly mutated genes in cancer and one of the most difficult proteins to target therapeutically is p53. The malfunction of p53 is crucial for the origin and spread of lung cancer. We aim develop new cancer drugs targeting p53 to help patients suffering from this terrible disease. Drugs able to reactivate the tumor-killing ability of p53 will be a significant new treatment option for thousands of lung cancer patients and will also improve treatment options for patients fighting other types of cancers.

Red button with telephone
Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
Red button of two hand prints
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

Button of turquoise LUNG FORCE swirl

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.